Figure 3

Kaplan Meier analysis of Validation Series A patients, stratified by gene expression risk group (A) and clinical stage (B). Kaplan Meier analysis was also performed on Stage IA patients from Validation Series A Stage stratified by AJCC stage (C), a clinical algorithm based on tumor size and age (D) and the 160-gene signature (C) for comparison purposes. The gene expression signature is able to more accurately identify stage I patients at risk of death within the first 24 months following diagnosis compared with clinical stage or combined clinical age + tumor size algorithm.